CO-1686: Phase II started

Clovis began the open-label, international, pivotal Phase II TIGER2 trial to evaluate 625 mg oral CO-1686 twice daily in 28-day cycles in 125 patients with T790M-positive NSCLC who progressed after their first and only tyrosine kinase inhibitor (TKI) therapy. TIGER2 is 1 of 3 registration trials of CO-1686 in the TIGER program. The Phase II/III TIGER1 trial in newly diagnosed EGFR mutant patients is slated to start mid-year, while the Phase III TIGER3 trial in T790M-positive patients who progressed after their first and only TKI therapy is slated to start this half. ...